Analysts Forecast Q4 Revenue of $13.28M, 2026 Forecasts Slashed 27% for Aquestive
Aquestive Therapeutics expects Q4 2025 revenue of $13.28 million and a loss per share of $0.13, after Q3 saw $12.81 million revenue and a $0.14 EPS miss. Over 90 days analysts cut 2026 revenue forecasts from $68.51 million to $49.89 million, while a $9.22 average one-year price target implies 124% upside.
1. Q4 Earnings Preview
Aquestive Therapeutics will report Q4 2025 results on March 5, with consensus revenue of $13.28 million and an expected loss per share of $0.13. In Q3 2025, revenue totalled $12.81 million and EPS came in at −$0.14, missing forecasts and prompting a 2.17% stock rise.
2. Analyst Estimate Revisions
Over the past 90 days, full-year 2025 revenue estimates barely shifted from $44.87 million to $44.81 million, while 2026 revenue projections fell from $68.51 million to $49.89 million. Earnings estimates remained at −$0.64 per share for 2025 and declined from −$0.52 to −$0.54 for 2026.
3. Price Targets and Ratings
Nine analysts set an average one-year price target of $9.22, ranging from $6.00 to $12.00 and implying 124% potential upside, contrasted with a GF Value estimate of $2.03 indicating a 51% downside. The average brokerage recommendation stands at 1.8, denoting an outperform rating.